Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Keryx diabetic nephropathy candidate fails

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

Diabetic nephropathy treatment Sulonex (sulodexide) was no better than placebo in a Phase III study, Keryx announces March 7. Sulonex failed to show a benefit in slowing kidney breakdown over time in type 2 diabetes with persistent microalbuminuria over placebo in the SUN-MICRO trial. The firm is now concentrating on other late stage candidates; perifosine is expected to enter a pivotal Phase III renal cell carcinoma trial by mid-year, and Zerenex (ferric citrate) is on track to start a high-dose Phase II hyperphosphatemia study in the first half of 2008

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

See All
UsernamePublicRestriction

Register

PS003797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By